Provided by Tiger Fintech (Singapore) Pte. Ltd.

CorMedix Inc.

8.50
+0.36004.42%
Post-market: 8.550.0500+0.59%19:58 EDT
Volume:1.92M
Turnover:16.02M
Market Cap:554.05M
PE:-27.91
High:8.57
Open:8.14
Low:8.04
Close:8.14
Loading ...

CorMedix Shares Plunge After 1H Guidance Missed Expectations

Dow Jones
·
25 Mar

CorMedix Down Over 31%, on Pace for Largest Percent Decrease Since August 2022 -- Data Talk

Dow Jones
·
25 Mar

Stock Track | CorMedix Plummets 24.79% Despite Positive Q4 Results as New Study Raises Growth Concerns

Stock Track
·
25 Mar

Stock Track | CorMedix Plummets 24.79% Pre-Market Despite Profitable Q4, New Study Plans Raise Concerns

Stock Track
·
25 Mar

CorMedix Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
25 Mar

CorMedix Is Maintained at Buy by D. Boral Capital

Dow Jones
·
25 Mar

Stock Track | CorMedix Shares Plunge 7.15% Pre-Market Despite Positive Q4 Results and 2025 Revenue Guidance

Stock Track
·
25 Mar

Stock Track | CorMedix Plunges 7.15% Pre-market on Mixed Q4 Results and Phase 3 Study Announcement

Stock Track
·
25 Mar

BRIEF-CorMedix Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Reuters
·
25 Mar

CorMedix Is Announcing Preliminary Net Revenue Guidance For First Half Of 2025 Of $50M–$60M

Benzinga
·
25 Mar

Cormedix Q4 2024 GAAP EPS $0.22 Beats $0.14 Estimate, Sales $31.21M Beat $26.53M Estimate

Benzinga
·
25 Mar

CorMedix Inc - to Commence Phase 3 Study of Defencath in Q2 2025

THOMSON REUTERS
·
25 Mar

CorMedix Inc - Prelim Net REV Guidance for H1 2025 $50 Mln - $60 Mln

THOMSON REUTERS
·
25 Mar

Press Release: CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Dow Jones
·
25 Mar

CorMedix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Benzinga
·
24 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
24 Mar

CorMedix Inc expected to post earnings of 14 cents a share - Earnings Preview

Reuters
·
21 Mar

CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025

GlobeNewswire
·
18 Mar

Truist Financial Remains a Buy on Cormedix (CRMD)

TIPRANKS
·
17 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Mobileye, Visionary Holdings, Wolfspeed

Reuters
·
08 Mar